MF Researcher Database

研究者一覧

詳細

大熊　遼太朗Ohkuma Ryotaro

■所属部署名腫瘍内科
■職名講師
Last Updated :2025/04/01

研究者情報

基本情報

プロフィール情報

  • 氏名

    大熊　遼太朗, Ohkuma Ryotaro

所属

  • 腫瘍内科, 講師

施設

  • 大学病院

学位

  • 博士(医学), 昭和大学, 2020年03月

業績

論文

  • Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit., Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, Baba Y, Isobe J, Funayama E, Tajima K, Shida M, Hamada K, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Tsunoda T, Yoshimura K., Cancer Sci., 2024年05月, 原著, 査読あり
  • Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody., Murayama Masakazu;Hosonuma Masahiro;Kuramasu Atsuo;Kobayashi Sei;Sasaki Akiko;Baba Yuta;Narikawa Yoichiro;Toyoda Hitoshi;Isobe Junya;Funayama Eiji;Tajima Kohei;Sasaki Aya;Maruyama Yuki;Yamazaki Yoshitaka;Shida Midori;Hamada Kazuyuki;Hirasawa Yuya;Tsurui Toshiaki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Risako;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Sambe Takehiko;Tsuji Mayumi;Wada Satoshi;Kobayashi Shinichi;Shimane Toshikazu;Tsunoda Takuya;Kobayashi Hitome;Kiuchi Yuji;Yoshimura Kiyoshi, Scientific reports, 14(1), 2024年05月, 原著, 査読あり
  • Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model., Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, Fujimoto Y, Ohkuma R, Suzuki R, Tsurui T, Mura E, Iriguchi N, Ishiguro T, Shimokawa M, Hirasawa Y, Kubota Y, Ariizumi H, Horiike A, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Fujishiro J, Hoffman RM, Tsunoda T, Wada S., Anticancer Res., 2024年01月, 原著, 査読あり
  • Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment., Hirasawa Yuya;Kubota Yutaro;Mura Emiko;Suzuki Risako;Tsurui Toshiaki;Iriguchi Nana;Ishiguro Tomoyuki;Ohkuma Ryotaro;Shimokawa Masahiro;Ariizumi Hirotsugu;Horiike Atsushi;Wada Satoshi;Ariyoshi Tomotake;Goto Satoru;Otsuka Koji;Murakami Masahiko;Kiuchi Yuji;Yoshimura Kiyoshi;Hoffman Robert M;Tsunoda Takuya, Anticancer research, 44(8):3397 - 3407, 2024年, 原著, 査読あり
  • Corrigendum: Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis., Shimizu Takashi;Inoue Eisuke;Ohkuma Ryotaro;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Frontiers in immunology, 14, 2023年12月, 原著, 査読あり
  • Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis., Shimizu Takashi;Inoue Eisuke;Ohkuma Ryotaro;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Frontiers in immunology, 14, 2023年11月, 原著, 査読あり
  • Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors., Ohkuma Ryotaro;Miura Sakiko;Muto Satoshi;Toyomasu Yoshitaka;Fujimoto Yuki;Ieguchi Katsuaki;Onishi Nobuyuki;Shimizu Takashi;Watanabe Makoto;Takayanagi Daisuke;Goshima Tsubasa;Horiike Atsushi;Hamada Kazuyuki;Ariizumi Hirotsugu;Shimokawa Masahiro;Hirasawa Yuya;Ishiguro Tomoyuki;Suzuki Risako;Iriguchi Nana;Tsurui Toshiaki;Mura Emiko;Takenoshita Sachiko;Numajiri Kazuki;Okabe Naoyuki;Yoshimura Kiyoshi;Tsuji Mayumi;Kiuchi Yuji;Yajima Toshiki;Ishida Hideyuki;Suzuki Hiroyuki;Yamochi Toshiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Frontiers in immunology, 14:1260492, 2023年09月, 原著, DOI:10.3389/fimmu.2023.1260492
  • Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy., Ohkuma Ryotaro;Fujimoto Yuki;Ieguchi Katsuaki;Onishi Nobuyuki;Watanabe Makoto;Takayanagi Daisuke;Goshima Tsubasa;Horiike Atsushi;Hamada Kazuyuki;Ariizumi Hirotsugu;Hirasawa Yuya;Ishiguro Tomoyuki;Suzuki Risako;Iriguchi Nana;Tsurui Toshiaki;Sasaki Yosuke;Homma Mayumi;Yamochi Toshiko;Yoshimura Kiyoshi;Tsuji Mayumi;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Oncology letters, 26(3):381, 2023年07月, 原著, DOI:10.3892/ol.2023.13967
  • Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary., Suzuki Risako;Hamada Kazuyuki;Ohkuma Ryotaro;Homma Mayumi;Tsurui Toshiaki;Iriguchi Nana;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Kubota Yutaro;Horiike Atsushi;Yoshimura Kiyoshi;Wada Satoshi;Yamochi Toshiko;Tsunoda Takuya, Frontiers in oncology, 13, 2023年07月, 原著
  • Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor., Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda and Kiyoshi Yoshimura, Front Immunol., 14:1164724, 2023年05月, 原著, 査読あり, DOI:10.3389/fimmu.2023.1164724
  • Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors., Lainé Alexandra;Gonzalez-Lopez Andrea M;Hasan Uzma;Ohkuma Ryotaro;Ray-Coquard Isabelle, Cancers, 15(7):2042, 2023年03月, 総説, DOI:10.3390/cancers15072042
  • 腫瘍細胞の糖鎖構造に着目した新規がん免疫療法の開発, 和田 聡; 家口 勝昭; 大熊 遼太郎; 高柳 大輔; 角田 卓也; 小林 真一, 臨床薬理の進歩, (43):98 - 108, 2022年06月, 原著
  • A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report., Hamada Kazuyuki;Yoshimura Kiyoshi;Oshinomi Kazuhiko;Hirasawa Yuya;Ariizumi Hirotsugu;Ohkuma Ryotaro;Shida Midori;Kubota Yutaro;Matsui Hiroto;Ishiguro Tomoyuki;Sambe Takehiko;Ishida Hiroo;Horiike Atsushi;Wada Satoshi;Iwamoto Sanju;Uchida Naoki;Ogawa Yoshio;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 101(2):e28339, 2022年01月, 原著, DOI:10.1097/MD.0000000000028339
  • Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies., Ohkuma Ryotaro;Ieguchi Katsuaki;Watanabe Makoto;Takayanagi Daisuke;Goshima Tsubasa;Onoue Rie;Hamada Kazuyuki;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Tsurutani Junji;Yoshimura Kiyoshi;Tsuji Mayumi;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Biomedicines, 9(12), 2021年12月, 原著, 査読あり
  • The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer., Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Aoki Takeshi;Murakami Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Pancreas, 50(2), 2021年, 原著, 査読あり
  • Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer., Kubota Yutaro;Yoshimura Kiyoshi;Hamada Kazuyuki;Hirasawa Yuya;Shida Midori;Taniguchi Makoto;Matsui Hiroto;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Norihiro;Ohkuma Ryotaro;Sambe Takehiko;Ishida Hiroo;Horiike Atsushi;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya, In vivo (Athens, Greece), 35(3), 2021年, 原著, 査読あり
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Hirasawa Yuya;Yoshimura Kiyoshi;Matsui Hiroto;Kubota Yutaro;Ishida Hiroo;Arai Jun;Sakaki Masashi;Oguro Nao;Shida Midori;Taniguchi Makoto;Hamada Kazuyuki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Ohkuma Ryotaro;Sambe Takehiko;Horiike Atsushi;Imamura Chiyo K;Shiozawa Eisuke;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Tate Genshu;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 100(23), 2021年, 原著, 査読あり
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer., Ohkuma Ryotaro;Yada Erica;Ishikawa Shumpei;Komura Daisuke;Kubota Yutaro;Hamada Kazuyuki;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Shida Midori;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Sasada Tetsuro;Aoki Takeshi;Murakami Masahiko;Norose Tomoko;Ohike Nobuyuki;Takimoto Masafumi;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, International journal of oncology, 58(1), 2020年11月, 原著, 査読あり
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Ando Kiyohiro;Hamada Kazuyuki;Shida Midori;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Matsui Hiroto;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Tsurutani Junji;Yoshimura Kiyoshi;Tsunoda Takuya;Kobayashi Shinichi;Wada Satoshi, Cancer immunology, immunotherapy : CII, 70(2), 2020年08月, 原著, 査読あり
  • Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients, MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;SEKIDO Masae;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;IKUSUE Toshikazu;KOBAYASHI Kouji;HISAMATSU Atsushi;TOSHIMA Hirokazu;SHIMADA Ken;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 85(6):1119 - 1128, 2020年06月, 原著, 査読あり
  • High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, 2020年01月, 原著, 査読あり
  • High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, 2020年01月, 原著, 査読あり
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors., Kiyohiro Ando; Kazuyuki Hamada; Makoto Watanabe; Ryotaro Ohkuma; Midori Shida; Rie Onoue; Yutaro Kubota; Hiroto Matsui; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Junji Tsurutani; Kiyoshi Yoshimura; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada, Anticancer research, 39(9):5195 - 5201, 2019年09月, 原著, 査読あり
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, 2019年09月, 原著, 査読あり
  • 腎癌および尿路上皮癌患者におけるバイオマーカー探索のための腸内細菌叢の研究, 下山　英明;直江　道夫;サト　プラサド　ネパール;平松　綾;松井　祐輝;鵜木　勉;中里　武彦;押野見　和彦;森田　順;前田　佳子;冨士　幸藏;小川　良雄;角田　卓也;吉村　清, 昭和学士会雑誌, 79(4):492 - 504, 2019年08月, 原著, 査読あり
  • Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil., Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y, Cancer chemotherapy and pharmacology, 83(6):1127 - 1135, 2019年06月, 原著, 査読あり
  • Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan., Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T, Cancer science, 109(12):3896 - 3901, 2018年12月, 原著, 査読あり
  • Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan., SATOH Etsuko;SASAKI Yasutsuna;OHKUMA Ryotaro;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;HAMADA Kazuyuki;KIUCHI Yuji;TSUNODA Takuya, Cancer Sci, 109(12):3896 - 3901, 2018年12月, 原著
  • Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan., SATOH Etsuko;SASAKI Yasutsuna;OHKUMA Ryotaro;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;HAMADA Kazuyuki;KIUCHI Yuji;TSUNODA Takuya, Cancer Sci, 109(12):3896 - 3901, 2018年12月, 原著
  • 癌免疫カンファレンスルーム(TOPICS 7)　免疫療法のバイオマーカー, 大熊 遼太朗;角田 卓也, 消化器外科, 41(8):1216, 2018年07月, 総説
  • 【がん患者の併存疾患を理解する】併存疾患を理解する　腎疾患, 大熊 遼太朗;久保田 祐太郎, がん看護, 23(1):18, 2018年01月, 総説

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.